NASDAQ$TOI
Oncology Institute Inc/The · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Reported financial results, highlighting a revenue increase of 36.6% and a gross profit increase of 87.6% compared to the prior year quarter.
The Oncology Institute (TOI) reported a 36.6% increase in consolidated revenue, reaching $71 million for Q4 2022. Gross profit increased by 87.6% to $16 million. The company ended the year with $132 million in cash, cash equivalents, and investments.
- Consolidated revenue increased by 36.6% to $71 million.
- Gross profit increased by 87.6% to $16 million.
- Net loss decreased to $9.5 million from $10.2 million in the prior year quarter.
- Ended the fiscal year with $132 million in cash, cash equivalents, and investments.
Headline financials
Revenue & EPS history
Oncology Institute · Revenue · Quarterly
$71.4M
Revenue by segment
Oncology Institute · $71.4M total across 3 segments · Q4 2022
- Patient Services$48M+51.4%67.2%
- Dispensary$21.6M+12.3%30.3%
- Clinical Trials & Other$1.83M+32.9%2.6%
Forward guidance
The Oncology Institute expects revenue between $290 million and $320 million, gross profit between $60 million and $70 million, and Adjusted EBITDA between $(25) million and $(28) million for fiscal year 2023.
Tailwinds
- Revenue is projected to grow by approximately 15% to 27% over 2022 revenue.
- Gross profit is expected to be between $60 million and $70 million.
- Value-based lives are expected to be between 1.75 million and 2.0 million.
- Interest expense is expected in the range of $4 million to $5 million.
- Depreciation and amortization is expected in the range of $4 million to $6 million.
Headwinds
- Adjusted EBITDA is projected to be between $(25) million and $(28) million.
- Uncertainties regarding taxes.
- Share-based compensation.
- Goodwill impairment charges.
- Change in fair value of liabilities.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2022
+2.6%
Avg return
Earnings day
+2.7%
Avg return
5 days after
+8.0%
Avg return
30 days after
62%
13 / 21 earnings
Positive
+28.9%
Q3 2025
Best reaction
-23.4%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +6.8% | +5.8% | +27.9% | |
| Q4 2025 | +8.4% | +37.4% | +17.6% | |
| Q3 2025 | +28.9% | +6.2% | +22.7% | |
| Q1 2025 | +28.3% | +17.3% | +4.2% | |
| Q4 2024 | +24.5% | +14.5% | +189.2% | |
| Q3 2024 | -23.4% | -43.8% | -5.1% | |
| Q2 2024 | -20.4% | -11.1% | -26.9% | |
| Q1 2024 | +3.6% | -26.5% | -46.6% | |
| Q4 2023 | +8.9% | -7.7% | -32.0% | |
| Q3 2023 | +5.7% | +46.6% | -27.6% | |
| Q2 2023 | -10.1% | -13.3% | +28.3% | |
| Q1 2023 | +4.2% | -6.3% | +29.2% | |
| Q4 2022 | +1.9% | -5.8% | -30.6% | |
| Q3 2022 | -4.3% | -35.5% | -66.4% | |
| Q2 2022 | +0.6% | -1.2% | -9.6% | |
| Q1 2022 | -14.7% | -11.8% | -6.5% | |
| Q2 2021 | +10.3% | +31.4% | +48.1% | |
| Q4 2020 | +10.3% | +31.4% | +48.1% | |
| Q4 2021 | -14.6% | +18.5% | +26.5% | |
| Q3 2021 | +0.0% | +10.0% | -23.6% | |
| Q1 2021 | -0.2% | +1.0% | +0.7% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro